Literature DB >> 16228235

Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.

S A Eshuis1, R P Maguire, K L Leenders, S Jonkman, P L Jager.   

Abstract

PURPOSE: Diagnosis of Parkinson's disease (PD) can be difficult. F-DOPA PET is able to quantify striatal dopa decarboxylase activity and storage capacity of F-dopamine, but is expensive and not generally available. FP-CIT binds to the dopamine transporter, and FP-CIT SPECT is cheaper and more widely available, but has a lower resolution. The aim of this study was to compare these two methods in the same patients with different stages of PD to assess their power in demonstrating deficits of the striatal dopaminergic system.
METHODS: Thirteen patients with de novo PD and 17 patients with advanced PD underwent FP-CIT SPECT and static F-DOPA PET. After data transfer to standard stereotactic space, a template with regions of interest was used to sample values of the caudate, putamen and an occipital reference region. The outcome value was striato-occipital ratios. Patients were clinically examined in the "off state" (UPDRS-III and H&Y stage).
RESULTS: Good correlations were found between striatal F-DOPA uptake and striatal FP-CIT uptake (r = 0.78) and between putaminal F-DOPA uptake and putaminal FP-CIT uptake (r = 0.84, both p < 0.0001). Both striatal uptake of FP-CIT and that of F-DOPA correlated moderately with H&amp;Y stage (rho = -0.52 for both techniques), UPDRS-III (rho = -0.38 for F-DOPA; rho = -0.45 for FP-CIT) and disease duration (rho = -0.59 for F-DOPA; rho = -0.49 for FP-CIT, all p < 0.05).
CONCLUSION: FP-CIT values correlate well with F-DOPA values. Both methods correlate moderately with motor scores and are equally able to distinguish patients with advanced PD from patients with de novo PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228235     DOI: 10.1007/s00259-005-1904-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  41 in total

Review 1.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease.

Authors:  T Brücke; S Djamshidian; G Bencsits; W Pirker; S Asenbaum; I Podreka
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

2.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

3.  Dopamine transporters decrease with age.

Authors:  N D Volkow; Y S Ding; J S Fowler; G J Wang; J Logan; S J Gatley; R Hitzemann; G Smith; S D Fields; R Gur
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

4.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

5.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

6.  Multimodal image coregistration and partitioning--a unified framework.

Authors:  J Ashburner; K Friston
Journal:  Neuroimage       Date:  1997-10       Impact factor: 6.556

7.  Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Authors:  H T Benamer; J Patterson; D J Wyper; D M Hadley; G J Macphee; D G Grosset
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

8.  Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.

Authors:  S Asenbaum; T Brücke; W Pirker; I Podreka; P Angelberger; S Wenger; C Wöber; C Müller; L Deecke
Journal:  J Nucl Med       Date:  1997-01       Impact factor: 10.057

9.  Brain dopamine transporter: gender differences and effect of chronic haloperidol.

Authors:  R Rivest; P Falardeau; T Di Paolo
Journal:  Brain Res       Date:  1995-09-18       Impact factor: 3.252

10.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12
View more
  25 in total

1.  Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease.

Authors:  Janey Prodoehl; Mathew Spraker; Daniel Corcos; Cynthia Comella; David Vaillancourt
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

2.  Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up.

Authors:  Swen Hesse; Karl Strecker; Dirk Winkler; Julia Luthardt; Christoph Scherfler; Annegret Reupert; Christian Oehlwein; Henryk Barthel; Jens-Peter Schneider; Florian Wegner; Philipp Meyer; Jürgen Meixensberger; Osama Sabri; Johannes Schwarz
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

3.  Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Zhemin Huang; Chengfeng Jiang; Ling Li; Qian Xu; Jingjie Ge; Ming Li; Yihui Guan; Jianjun Wu; Jian Wang; Chuantao Zuo; Huan Yu; Ping Wu
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-10       Impact factor: 6.200

4.  The role of the deep convolutional neural network as an aid to interpreting brain [18F]DOPA PET/CT in the diagnosis of Parkinson's disease.

Authors:  Arnoldo Piccardo; Roberto Cappuccio; Gianluca Bottoni; Diego Cecchin; Luca Mazzella; Alessio Cirone; Sergio Righi; Martina Ugolini; Pietro Bianchi; Pietro Bertolaccini; Elena Lorenzini; Michela Massollo; Antonio Castaldi; Francesco Fiz; Laura Strada; Angelina Cistaro; Massimo Del Sette
Journal:  Eur Radiol       Date:  2021-03-08       Impact factor: 5.315

5.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

6.  18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.

Authors:  Jian Wang; Cuan-Tao Zuo; Yu-Ping Jiang; Yi-Hui Guan; Zheng-Ping Chen; Jing-De Xiang; Li-Qin Yang; Zheng-Tong Ding; Jian-Jun Wu; Hui-Lin Su
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

7.  Functional brain imaging: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-12-01

8.  The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.

Authors:  Nevein Ibrahim; Joanna Kusmirek; Aaron F Struck; John M Floberg; Scott B Perlman; Catherine Gallagher; Lance T Hall
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28

9.  Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Authors:  S A Eshuis; P L Jager; R P Maguire; S Jonkman; R A Dierckx; K L Leenders
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

10.  Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.

Authors:  Valentina Berti; Alberto Pupi; Silvia Ramat; Eleonora Vanzi; Maria Teresa De Cristofaro; Giannantonio Pellicanò; Francesco Mungai; Paolo Marini; Sandro Sorbi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.